Patents by Inventor Jilly Evans

Jilly Evans has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of cysteinyl leukotriene 2 receptor antagonists
    Publication number: 20070197585
    Abstract: The instant invention provides a method for treating and/or reducing the risk for atherosclerosis, pulmonary fibrosis and stroke, comprising administering an effective amount of a cysteinyl leukotriene 2 receptor antagonist, including a selective cysteinyl leuoktriene 2 receptor antagonist and a dual cysteinyl leukotriene 1 receptor and cysteinyl leukotriene 2 receptor antagonist to a patient in need of such treatment.
    Type: Application
    Filed: February 24, 2005
    Publication date: August 23, 2007
    Inventors: Jilly Evans, Anthony Ford-Hutchinson, John Hutchinson, Robert Young
  • Method for the prevention and/or treatment of atherosclerosis
    Publication number: 20060004040
    Abstract: The instant invention provides a method for treating and/or reducing the risk for atherosclerosis comprising administering an effective amount of a FLAP inhibitor alone or in combination with another anti-atherosclerotic agent to a patient in need of such treatment.
    Type: Application
    Filed: August 22, 2003
    Publication date: January 5, 2006
    Inventors: Jilly Evans, John Hutchinson
  • Method of treating colonic adenomas
    Patent number: 6649649
    Abstract: This invention is directed to a method of retarding or preventing the transformation of a colonic adenoma to a colonic adenocarcinoma comprising the administration to a patient with FAP or a patient with one or more of said adenomas a non-toxic therapeutically effective amount of NSAID, said amount effective to inhibit the PGHS-2 in said adenoma. The preferred method comprises the administration of a specific PGHS-2 inhibiting agent as defined herein.
    Type: Grant
    Filed: March 2, 1999
    Date of Patent: November 18, 2003
    Assignees: Merck & Co., Inc., Merck Frosst Canada, & Co.
    Inventors: Stacia Kargman, Thomas J. Simon, Jilly Evans
  • Method of treating colonic adenomas
    Patent number: 6593361
    Abstract: This invention is directed to a method of retarding or preventing the transformation of a colonic adenoma to a colonic adenocarcinoma comprising the administration to a patient with FAP or a patient with one or more of said adenomas a non-toxic therapeutically effective amount of NSAID, said amount effective to inhibit the PGHS-2 in said adenoma. The preferred method comprises the administration of a specific PGHS-2 inhibiting agent as defined herein.
    Type: Grant
    Filed: October 12, 2001
    Date of Patent: July 15, 2003
    Inventors: Stacia Kargman, Jilly Evans, Thomas J. Simon
  • Method of treating colonic adenomas
    Publication number: 20020045605
    Abstract: This invention is directed to a method of retarding or preventing the transformation of a colonic adenoma to a colonic adenocarcinoma comprising the administration to a patient with FAP or a patient with one or more of said adenomas a non-toxic therapeutically effective amount of NSAID, said amount effective to inhibit the PGHS-2 in said adenoma. The preferred method comprises the administration of a specific PGHS-2 inhibiting agent as defined herein.
    Type: Application
    Filed: October 12, 2001
    Publication date: April 18, 2002
    Applicant: Merck & Co.
    Inventors: Stacia Kargman, Jilly Evans, Thomas J. Simon
  • Method of treating colonic adenomas
    Patent number: 5968974
    Abstract: This invention is directed to a method of retarding or preventing the transformation of a colonic adenoma to a colonic adenocarcinoma comprising the administration to a patient with FAP or a patient with one or more of said adenomas a non-toxic therapeutically effective amount of NSAID, said amount effective to inhibit the PGHS-2 in said adenoma. The preferred method comprises the administration of a specific PGHS-2 inhibiting agent as defined herein.
    Type: Grant
    Filed: October 10, 1997
    Date of Patent: October 19, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Stacia Kargman, Jilly Evans, Thomas J. Simon